Home › Funds › Avoro Capital Advisors LLC › ARWR

Avoro Capital Advisors LLC position in ARWR

ARROWHEAD PHARMACEUTICALS IN · Health Care

Avoro Capital Advisors LLC reported holding 11,000,000 shares of ARWR (ARROWHEAD PHARMACEUTICALS IN) in its Q3 2026 13F filing — a position valued at US$720.0M, representing 7.45% of its reported portfolio and ranking #7 among its reported holdings. Avoro Capital Advisors LLC has disclosed ARWR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)11.00M sh
Reported value held$719.95M
Portfolio Weight7.45%
First reportedQ3 2023
Last changeReduce
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Avoro Capital Advisors LLC's ARWR position evolved

Avoro Capital Advisors LLC first disclosed a stake in ARWR in Q3 2023 at 565,000 shares (US$15.2M). The position peaked in Q2 2026 at 11,355,555 shares, worth US$925.6M. Across 13 filings, Avoro Capital Advisors LLC increased the stake 7 time(s), trimmed it 3 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 11,000,000 shares valued at US$720.0M — a reduction of -355,555 shares quarter over quarter.. Notable position changes include a 100% increase in Q4 2023 (shares fell 7% over the following quarter), a 657% increase in Q1 2024 (shares fell 9% over the following quarter), a 25% increase in Q4 2024 (shares fell 32% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 565.00K $15.18M New
Q4 2023 1.13M $34.58M Add
Q1 2024 8.56M $244.69M Add
Q2 2024 8.89M $231.02M Add
Q3 2024 8.89M $172.18M Hold
Q4 2024 11.11M $208.89M Add
Q1 2025 11.11M $141.56M Hold
Q2 2025 10.60M $167.48M Reduce
Q3 2025 10.90M $375.94M Add
Q4 2025 10.62M $705.39M Reduce
Q1 2026 10.70M $670.89M Add
Q2 2026 11.36M $925.59M Add
Q3 2026 11.00M $719.95M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ARWR and 13F data

ARWR (ARROWHEAD PHARMACEUTICALS IN) is a Health Care company. 42 other funds we track also report a position in ARWR — the largest reported positions include FRED ALGER MANAGEMENT, LLC (US$269.1M), BAKER BROS. ADVISORS LP (US$162.4M), Siren, L.L.C. (US$149.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ARWR

All ARWR fund holders →

FAQ

How long has Avoro Capital Advisors LLC held ARWR?

Avoro Capital Advisors LLC has disclosed ARWR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Avoro Capital Advisors LLC's current position in ARWR?

As of Q3 2026, Avoro Capital Advisors LLC holds 11.00M shares of ARWR (ARROWHEAD PHARMACEUTICALS IN), valued at $719.95M, representing 7.45% of its reported portfolio and ranking #7.

Has Avoro Capital Advisors LLC been buying or selling ARWR?

In the latest 13F filing (Q3 2026), Avoro Capital Advisors LLC reduced its position in ARWR. The position peaked in Q2 2026 at 11.36M shares.

Which other funds hold ARWR?

Other major institutional holders of ARWR include FRED ALGER MANAGEMENT, LLC, BAKER BROS. ADVISORS LP, Siren, L.L.C., among 42 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.